ALX Oncology Holdings Inc.ALXONASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +7.77% | +6.46% | +3.11% | +1.68% | +2.80% |
| Weighted Average Shares Diluted Growth | +7.77% | +6.46% | +3.11% | +1.68% | +2.80% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +0.00% | -17.18% | -89.33% | -100.00% | +0.00% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -39.08% | -43.15% | -55.59% | -55.46% | -60.04% |
| Book Value per Share Growth | -44.43% | -49.49% | -60.79% | -67.79% | -77.76% |
| Debt Growth | -42.41% | -40.80% | -7.38% | -55.79% | -47.32% |
| R&D Expense Growth | -43.68% | -24.68% | -47.99% | -34.11% | -25.02% |
| SG&A Expenses Growth | +13.50% | +36.03% | -18.05% | -16.49% | -24.08% |